Loading...
Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC
Antonia, S Villegas, A Daniel, D Vicente, D Murakami, S Hui, R Kurata, T Chiappori, A Lee, KH de Wit, M
Antonia, S
Villegas, A
Daniel, D
Vicente, D
Murakami, S
Hui, R
Kurata, T
Chiappori, A
Lee, KH
de Wit, M
Citations
Altmetric:
Abstract
Authors
Antonia, S
Villegas, A
Daniel, D
Vicente, D
Murakami, S
Hui, R
Kurata, T
Chiappori, A
Lee, KH
de Wit, M
Cho, BC
Bourhaba, M
Quantin, X
Tokito, T
Mekhail, T
Planchard, D
Kim, Y
Karapetis, C
Hiret, S
Ostoros, G
Kubota, K
Gray, J
Paz-Ares, L
De Carpeno, JDC
Faivre-Finn, Corinne
Reck, M
Vansteenkiste, J
Spigel, D
Wadsworth, C
Taboada, M
Dennis, P
Ozguroglu, M
Villegas, A
Daniel, D
Vicente, D
Murakami, S
Hui, R
Kurata, T
Chiappori, A
Lee, KH
de Wit, M
Cho, BC
Bourhaba, M
Quantin, X
Tokito, T
Mekhail, T
Planchard, D
Kim, Y
Karapetis, C
Hiret, S
Ostoros, G
Kubota, K
Gray, J
Paz-Ares, L
De Carpeno, JDC
Faivre-Finn, Corinne
Reck, M
Vansteenkiste, J
Spigel, D
Wadsworth, C
Taboada, M
Dennis, P
Ozguroglu, M
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. PL02.01 Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. J Thorac Oncol. 2018;13(10):S184.